Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.40 |
| ▸ | FLT4 | P35916 | 8/20 | 0.40 |
| ▸ | CSF1R | P07333 | 8/20 | 0.40 |
| ▸ | FLT3 | P36888 | 7/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104074 | 0.91 | KDR (0.49) | KDRPDGFRBFLT4CSF1RFLT3 | |
| SCHEMBL7105547 | 0.86 | MAPT (0.51) | KDRBRAFPDGFRBFLT4CSF1R | |
| SCHEMBL7104206 | 0.80 | ITGB1 (0.52) | — | |
| SCHEMBL7259000 | 0.79 | DRD1 (0.37) | — | |
| SCHEMBL7099861 | 0.78 | ITGB1 (0.35) | — | |
| SCHEMBL7104235 | 0.75 | ITGB1 (0.66) | KDRBRAFMAPK14TNNI3KPDGFRB | |
| SCHEMBL7099959 | 0.74 | RAB9A (0.46) | KDRMAPK14PDGFRBFLT4CSF1R | |
| SCHEMBL7259116 | 0.74 | ITGB1 (0.33) | — | |
| SCHEMBL7259188 | 0.73 | ITGB1 (0.32) | — | |
| SCHEMBL7105093 | 0.72 | ITGB1 (0.65) | KDRBRAFMAPK14TNNI3KPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | KDR 285/4885BRAF 2471/4885MAPK14 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.